AFN0328
/ Anhui Anke Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 21, 2026
A phase 1 dose-escalation and -expansion study of AFN0328, a novel mRNA-based immunotherapy, in patients with HPV16/18-associated high-grade squamous intraepithelial lesions.
(ASCO 2026)
- P | "AFN0328 demonstrated favorable safety and tolerability with robust immune responses in HPV16/18-associated HSIL, supporting further clinical development as an immunotherapy for HPV-driven precancerous disease. Summary of safety and immunogenicity outcomes. *Observed in evaluable patients during interim follow-up."
Clinical • IO biomarker • P1 data • Infectious Disease
1 to 1
Of
1
Go to page
1